Pluristem Therapeutics Inc (PSTI)

[Scott999]

Seems like they can grow other types of cells in the Bioreactors. Unless they were lying in their report. So yes manufacturing possibilies have been wasted for years. Biggest gaff this company has made to date. Would have been able to fund all their trials with no need for dilution, or not nearly to the extent they have. Could have been the leader in this field, but chose to keep it to themselves and build a big plant so they can all watch through the glass like kids at a candy store, and grow little or next to nothing. Impresses the ladies I heard though.

And did you notice the $50,000 in revenue this quarter at a cost of $2,000. No margins there. Manufacturing is a waste of time. No money to be made there. Besides, we can always dilute.

•Our PluriX™ Bioreactor system can be used to expand umbilical cord blood hematopoietic stem cells for use in adult transplants. With the assistance of our PluriX™ Bioreactor system, one portion of umbilical cord blood hematopoietic stem cells can be expanded to quantities enough for a number of transplants. This means that healthy autologus umbilical cord blood hematopoietic stem cells can be taken at the time of birth, expanded into mature hematopoietic stem cells and stored by a cell bank in the instance that it may be needed by that specific patient at a later date. This will eliminate the current practice of transplanting cancerous cells back into the patient.


•Our PluriX™ Bioreactor system can be used for allogenic expansion, i.e. to expand the hematopoietic stem cells from donors other than the patient himself. Allogenic stem cells can also be expanded for use as a transplant source for adults in the instances that enough stem cells are not attainable from a particular donor.


•Our PluriX™ Bioreactor system can also be used for autologus proliferation, i.e. to expand the hematopoietic stem cells taken from the transplant patients themselves. Contrary to any existing available technologies known to us, our PluriX™ Bioreactor system will allow the use of autologus bone marrow transplantation in the case that healthy cells are not clearly attainable from the patient.

https://www.sec.gov/Archives/edgar/data/1158780/000108503704001033/f10ksb063004.htm